Oslo, Norway, July 19th, 2022: Cardiovascular DX company CardiNor AS today announces that it has signed an exclusive agreement with IBL-America for sales of the CardiNor Secretoneurin ELISA test in the US. CardiNor aims to spread awareness of this important new frontline biomarker and pave the way for future commercialization upon US regulatory clearance to research institutes, clinical research organizations and pharmaceutical companies.

In contrast to other commonly used biomarkers such as cardiac troponins and N-terminal proB-type natriuretic peptide (NT-proBNP), secretoneurin (SN) is associated with biological processes linked to heart cell calcium, a key mechanism in the regulation of heart rhythm and has been described as the “missing link biomarker” in cardiovascular disease risk assessment¹. This unique biological function may explain why SN has been shown to be an independent and strong predictor of mortality in all major patient cohorts tested, including patients with ventricular arrhythmia, acute heart failure, and acute respiratory failure patients with CVD and severe sepsis^2,3,4,5. CardiNor has a comprehensive clinical program to further strengthen and widen the clinical documentation.

“Cardiovascular disease research is a key market for IBL-America and CardiNor’s Secretoneurin ELISA test is an excellent addition to our portfolio. We are convinced our customers will find it an invaluable research tool,” says Mark Kowal, President/CEO, IBL-America.

“We are delighted to work with IBL-America, a company with extensive experience in distributing high quality laboratory research and clinical products in the US. IBL has a very strong position with the major reference laboratories and with their own CLIA laboratory they can support our planned US regulatory activities. Our test is generating a great deal of interest worldwide and signing this deal with IBL-America will enable us to increase our presence in the important US research market,” added Dag Christiansen, CEO of CardiNor.

The CardiNor SN assay is based on work by Professor Torbjørn Omland and his research group at Akershus University Hospital in Norway.

References:

• 1.Mark E. Anderson, Editorial: Will Secretoneurin Be the Next Big Thing? J Am Coll Cardiol 2015,65
• 2.Ottesen et.al, Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol 2015 Feb 3;65(4):339-351
• 3.Røsjø et.al, on behalf of the FINNSEPSIS and FINNALI Study Groups. Prognostic Value of Secretoneurin in Critically Ill Patients With Infections. Crit Care Med 2016 Oct;44(10):1882-90
• 4.Myhre et.al, Prognostic Value of Secretoneurin in Patients with Acute Respiratory Failure: Data from the FINNALI Study. Clin Chem 2016 Oct;62(10):1380-89
• 5.Røsjø et al, for the ALBIOS Biomarkers Study Investigators. Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock: Data From the Albumin Italian Outcome Sepsis Study. Crit Care Med 2018.

About CardiNor

CardiNor is a Norwegian Diagnostics company founded in 2015 with the purpose of fighting the Heart Failure (HF) epidemic, by leveraging the patented and exclusive rights to the commercial introduction of Secretoneurin (SN), a blood-based biomarker that provides prognostic insights for several cardiovascular diseases (CVD). The team is focused on developing scalable cardiac biomarker tests to quantify the levels of SN in human blood, addressing a vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring.

About IBL-America

For over 25 years, IBL-America has provided high-quality laboratory reagent assays, antibodies and proteins for research and clinical testing in various areas including cardiovascular disease. IBL-America also has the capability to provide technical support with their experienced technical team and their modern, fully-equipped internal laboratory.